{"id":57900,"date":"2026-02-25T13:31:04","date_gmt":"2026-02-25T05:31:04","guid":{"rendered":"https:\/\/flcube.com\/?p=57900"},"modified":"2026-02-25T13:31:05","modified_gmt":"2026-02-25T05:31:05","slug":"cansino-biologics-wins-nmpa-approval-for-menhycia-age-expansion-mcv4-now-covers-children-up-to-6-years","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=57900","title":{"rendered":"CanSino Biologics Wins NMPA Approval for Menhycia Age Expansion \u2013 MCV4 Now Covers Children Up to 6 Years"},"content":{"rendered":"\n<p><strong>CanSino Biologics (<a href=\"https:\/\/www.google.com\/finance\/quote\/6185:HKG\">HKG:\u202f6185<\/a>)<\/strong> announced that China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has approved a <strong>supplementary market filing<\/strong> for its <strong>ACYW135 Meningococcal Conjugate Vaccine (CRM197)<\/strong> (MCV4, trade name: <strong>Menhycia<\/strong>). The approval expands the indicated age range from <strong>3 months to 3 years (47 months)<\/strong> to <strong>3 months to 6 years (83 months)<\/strong>, significantly broadening the vaccine&#8217;s addressable pediatric population.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>CanSino Biologics (HKG:\u202f6185)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Menhycia (ACYW135 Meningococcal Conjugate Vaccine, CRM197)<\/td><\/tr><tr><td><strong>Vaccine Class<\/strong><\/td><td>Quadrivalent meningococcal conjugate vaccine (MCV4)<\/td><\/tr><tr><td><strong>Regulatory Action<\/strong><\/td><td>Supplementary market filing approved<\/td><\/tr><tr><td><strong>Previous Age Range<\/strong><\/td><td>3 months to 3 years (47 months)<\/td><\/tr><tr><td><strong>New Age Range<\/strong><\/td><td>3 months to 6 years (83 months)<\/td><\/tr><tr><td><strong>Original Approval<\/strong><\/td><td>December 2021 (China)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Prevention of epidemic cerebrospinal meningitis caused by Neisseria meningitidis A, C, Y, and W135<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-menhycia\">Product Profile \u2013 Menhycia<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Vaccine Type:<\/strong> <strong>Quadrivalent conjugate vaccine<\/strong> targeting four meningococcal serogroups (A, C, Y, W135)<\/li>\n\n\n\n<li><strong>Carrier Protein:<\/strong> <strong>CRM197<\/strong> \u2013 non\u2011toxic diphtheria toxin mutant used as conjugate carrier<\/li>\n\n\n\n<li><strong>Age Expansion Impact:<\/strong> <strong>+36 months<\/strong> of additional coverage, extending protection through early childhood<\/li>\n\n\n\n<li><strong>Disease Prevention:<\/strong> Epidemic cerebrospinal meningitis \u2013 a severe bacterial infection with high mortality and morbidity in pediatric populations<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Expansion:<\/strong> The age range extension <strong>doubles the addressable pediatric window<\/strong>, capturing children aged 3\u20136 years who previously required alternative vaccination strategies or remained unprotected.<\/li>\n\n\n\n<li><strong>Competitive Positioning:<\/strong> Menhycia strengthens its position in China&#8217;s <strong>quadrivalent meningococcal vaccine market<\/strong>, competing against domestic and imported MCV4 products.<\/li>\n\n\n\n<li><strong>Pediatric Vaccine Portfolio:<\/strong> The approval reinforces CanSino&#8217;s <strong>pediatric infectious disease franchise<\/strong>, complementing its COVID\u201119 and other vaccine offerings.<\/li>\n\n\n\n<li><strong>Public Health Impact:<\/strong> Expanded coverage aligns with China&#8217;s <strong>National Immunization Program<\/strong> goals to reduce meningococcal disease burden in high\u2011risk pediatric populations.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>China Meningococcal Disease Burden<\/strong><\/td><td>Significant public health concern; highest incidence in children under 5<\/td><\/tr><tr><td><strong>MCV4 Market Growth<\/strong><\/td><td>Quadrivalent vaccines replacing monovalent\/conjugate alternatives due to broader serogroup protection<\/td><\/tr><tr><td><strong>Age Expansion Value<\/strong><\/td><td>Additional 3\u2011year coverage window increases vaccination compliance and reduces disease risk in preschool\u2011age children<\/td><\/tr><tr><td><strong>Revenue Potential<\/strong><\/td><td>Expanded indication drives volume growth in China&#8217;s ~15\u202fmillion annual birth cohort<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding market uptake, revenue projections, and competitive positioning for Menhycia. Actual results may differ due to risks including pricing pressures, competitive launches, and vaccination program adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2026022400328_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026022400328_c.\"><\/object><a id=\"wp-block-file--media-95812e87-775d-4607-a380-dfc2b4178ac9\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2026022400328_c.pdf\">2026022400328_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2026022400328_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-95812e87-775d-4607-a380-dfc2b4178ac9\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CanSino Biologics (HKG:\u202f6185) announced that China&#8217;s National Medical Products Administration (NMPA) has approved a supplementary&#8230;<\/p>\n","protected":false},"author":1,"featured_media":57904,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[466,884,15,12],"class_list":["post-57900","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cansino-biologics","tag-hkg-6185","tag-product-approvals","tag-vaccine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CanSino Biologics Wins NMPA Approval for Menhycia Age Expansion \u2013 MCV4 Now Covers Children Up to 6 Years - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"CanSino Biologics (HKG:\u202f6185) announced that China&#039;s National Medical Products Administration (NMPA) has approved a supplementary market filing for its ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4, trade name: Menhycia). The approval expands the indicated age range from 3 months to 3 years (47 months) to 3 months to 6 years (83 months), significantly broadening the vaccine&#039;s addressable pediatric population.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=57900\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CanSino Biologics Wins NMPA Approval for Menhycia Age Expansion \u2013 MCV4 Now Covers Children Up to 6 Years\" \/>\n<meta property=\"og:description\" content=\"CanSino Biologics (HKG:\u202f6185) announced that China&#039;s National Medical Products Administration (NMPA) has approved a supplementary market filing for its ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4, trade name: Menhycia). The approval expands the indicated age range from 3 months to 3 years (47 months) to 3 months to 6 years (83 months), significantly broadening the vaccine&#039;s addressable pediatric population.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=57900\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-25T05:31:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-25T05:31:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2502.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57900#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57900\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CanSino Biologics Wins NMPA Approval for Menhycia Age Expansion \u2013 MCV4 Now Covers Children Up to 6 Years\",\"datePublished\":\"2026-02-25T05:31:04+00:00\",\"dateModified\":\"2026-02-25T05:31:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57900\"},\"wordCount\":381,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57900#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2502.webp\",\"keywords\":[\"CanSino Biologics\",\"HKG: 6185\",\"Product approvals\",\"Vaccine\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57900#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57900\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=57900\",\"name\":\"CanSino Biologics Wins NMPA Approval for Menhycia Age Expansion \u2013 MCV4 Now Covers Children Up to 6 Years - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57900#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57900#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2502.webp\",\"datePublished\":\"2026-02-25T05:31:04+00:00\",\"dateModified\":\"2026-02-25T05:31:05+00:00\",\"description\":\"CanSino Biologics (HKG:\u202f6185) announced that China's National Medical Products Administration (NMPA) has approved a supplementary market filing for its ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4, trade name: Menhycia). The approval expands the indicated age range from 3 months to 3 years (47 months) to 3 months to 6 years (83 months), significantly broadening the vaccine's addressable pediatric population.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57900#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57900\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57900#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2502.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2502.webp\",\"width\":1080,\"height\":608,\"caption\":\"CanSino Biologics Wins NMPA Approval for Menhycia Age Expansion \u2013 MCV4 Now Covers Children Up to 6 Years\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57900#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CanSino Biologics Wins NMPA Approval for Menhycia Age Expansion \u2013 MCV4 Now Covers Children Up to 6 Years\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CanSino Biologics Wins NMPA Approval for Menhycia Age Expansion \u2013 MCV4 Now Covers Children Up to 6 Years - Insight, China&#039;s Pharmaceutical Industry","description":"CanSino Biologics (HKG:\u202f6185) announced that China's National Medical Products Administration (NMPA) has approved a supplementary market filing for its ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4, trade name: Menhycia). The approval expands the indicated age range from 3 months to 3 years (47 months) to 3 months to 6 years (83 months), significantly broadening the vaccine's addressable pediatric population.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=57900","og_locale":"en_US","og_type":"article","og_title":"CanSino Biologics Wins NMPA Approval for Menhycia Age Expansion \u2013 MCV4 Now Covers Children Up to 6 Years","og_description":"CanSino Biologics (HKG:\u202f6185) announced that China's National Medical Products Administration (NMPA) has approved a supplementary market filing for its ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4, trade name: Menhycia). The approval expands the indicated age range from 3 months to 3 years (47 months) to 3 months to 6 years (83 months), significantly broadening the vaccine's addressable pediatric population.","og_url":"https:\/\/flcube.com\/?p=57900","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-25T05:31:04+00:00","article_modified_time":"2026-02-25T05:31:05+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2502.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=57900#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=57900"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CanSino Biologics Wins NMPA Approval for Menhycia Age Expansion \u2013 MCV4 Now Covers Children Up to 6 Years","datePublished":"2026-02-25T05:31:04+00:00","dateModified":"2026-02-25T05:31:05+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=57900"},"wordCount":381,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=57900#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2502.webp","keywords":["CanSino Biologics","HKG: 6185","Product approvals","Vaccine"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=57900#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=57900","url":"https:\/\/flcube.com\/?p=57900","name":"CanSino Biologics Wins NMPA Approval for Menhycia Age Expansion \u2013 MCV4 Now Covers Children Up to 6 Years - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=57900#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=57900#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2502.webp","datePublished":"2026-02-25T05:31:04+00:00","dateModified":"2026-02-25T05:31:05+00:00","description":"CanSino Biologics (HKG:\u202f6185) announced that China's National Medical Products Administration (NMPA) has approved a supplementary market filing for its ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4, trade name: Menhycia). The approval expands the indicated age range from 3 months to 3 years (47 months) to 3 months to 6 years (83 months), significantly broadening the vaccine's addressable pediatric population.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=57900#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=57900"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=57900#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2502.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2502.webp","width":1080,"height":608,"caption":"CanSino Biologics Wins NMPA Approval for Menhycia Age Expansion \u2013 MCV4 Now Covers Children Up to 6 Years"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=57900#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CanSino Biologics Wins NMPA Approval for Menhycia Age Expansion \u2013 MCV4 Now Covers Children Up to 6 Years"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2502.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57900","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=57900"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57900\/revisions"}],"predecessor-version":[{"id":57905,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57900\/revisions\/57905"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/57904"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=57900"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=57900"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=57900"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}